Immune activation, capacity, and the cost of escalation
Escalation is built into conventional cancer care.
When something doesn’t work, we intensify. Increase the dose. Add another agent. Move to the next line. The logic is clean and measuable: more pressure should produce more effect. This is the way we create protocols and first and second line treatments. In cytotoxic oncology, that logic has often held up.
In immuno-oncology, it becomes far less reliable.
I understand escalation as a response to uncertainty. When outcomes are unclear, doing more feels safer than doing less. There is comfort in action, particularly when disease carries the weight it does.
At the bedside, escalation may look different.
There is a point, often poorly defined, where additional intervention stops increasing benefit and begins to erode tolerance. Not because the therapy is wrong, but because the system receiving it no longer has reserve. It is no longer able to ‘return to baseline’. The immune system doesn’t simply fail at that point. It may be becoming tired and disorganized.
This is not always obvious on imaging or labs.
Early on, escalation may still produce target engagement. Biomarkers may move. Tumor burden may hold steady or even improve slightly. But recovery between cycles shortens. Sleep fragments. Glucose becomes more volatile. Inflammatory signals rise without direction or resolution. The system is responding, but it is no longer integrating.
Escalation assumes capacity. Capacity is not infinite.
One of the central misunderstandings in cancer immunology is the assumption that activation alone is sufficient. In reality, immune systems require education before activation becomes coherent. Without that education, without appropriate antigen recognition, context, and signaling hierarchy, activation can amplify noise rather than precision.
An immune response that is strong but misdirected is not effective. It’s like running a race without even being on the right racetrack.
In heavily pretreated patients, immune systems are often operating near their ceiling. They may be capable of activation, but not discrimination. Adding intensity at that point does not deepen response. It broadens inflammation. The immune system signals danger without clarity, and what looks like resistance may actually be confusion.
This is where escalation quietly stops helping.
We tend to describe this moment using disease-centered language.
We call it refractory disease.
We call it lack of response.
We rarely call it inadequate immune instruction or exceeded system capacity.
At the bedside, the earliest signal that escalation has stopped helping is not progression. It is intolerance. A body that can no longer recover between interventions. A nervous system that remains activated long after treatment ends. A patient who becomes smaller in the room even as therapy intensifies.
There is a difference between an immune system that cannot respond and one that has not been properly guided.
Effective immune engagement is not simply about stimulation. It depends on sequencing - on whether the immune system has been shown what to respond to, how to respond, and when to stand down. Without that sequence, escalation becomes blunt force.
In immune-mediated disease, stability can represent containment — a negotiated balance in which the immune system has learned to recognize the threat without exhausting itself in the process. Escalating indiscriminately in that moment can fracture coherence and undo hard-won equilibrium.
This does not mean escalation is wrong. There are moments when it is lifesaving — rapid progression, impending organ compromise, clear immune non-engagement. The problem is not escalation itself. The problem is escalation that is disconnected from immune readiness.
As a scientist, I am trained to pursue marginal gains.
As a clinician, I am trained to notice when marginal gains come at disproportionate biological cost.
Those perspectives don’t always agree.
What experience has taught me is that escalation should be treated like any other powerful intervention: it requires the right context, the right timing, and a system capable of integrating the signal. Without those, more treatment does not mean more care.
Sometimes the most skilled decision in cancer care is not knowing what to add next — but recognizing when the immune system needs clarity more than intensity.
That moment rarely announces itself.
It has to be noticed.
References:
-
Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A.
The hallmarks of successful anticancer immunotherapy.
Science Translational Medicine.
https://www.science.org/doi/10.1126/scitranslmed.aao4489 -
Wherry EJ, Kurachi M.
Molecular and cellular insights into T cell exhaustion.
Nature Reviews Immunology.
https://www.nature.com/articles/nri.2015.1 -
Schietinger A, Greenberg PD.
Tolerance and exhaustion: defining mechanisms of T cell dysfunction.
Trends in Immunology.
https://www.sciencedirect.com/science/article/pii/S1471490614001627 -
Mellman I, Coukos G, Dranoff G.
Cancer immunotherapy comes of age.
Nature.
https://www.nature.com/articles/nature10673 -
Palucka K, Banchereau J.
Dendritic-cell-based therapeutic cancer vaccines.
Immunity.
https://www.sciencedirect.com/science/article/pii/S1074761313004802 -
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D.
Dendritic cells in cancer immunology and immunotherapy.
Nature Reviews Immunology.
https://www.nature.com/articles/s41577-020-00437-z -
Munn DH, Bronte V.
Immune suppressive mechanisms in the tumor microenvironment.
Nature Reviews Cancer.
https://www.nature.com/articles/nrc.2016.23 -
Decker WK, Halpert MM, et al. Antigen presentation by dendritic cells governs T-cell polarization and immune specificity. Blood.
-
Decker WK, Xing D, Li S, et al. Th-1 polarization is regulated by dendritic cell comparison of MHC class I and class II antigens. Blood. 2009.